This article is more than 5 years old. Information may no longer be current.

EMA accepts application for Oxervate for treatment of neurotrophic keratitis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A registration application for Oxervate eye drops for the treatment of moderate and severe neurotrophic keratitis in adults has been accepted by the European Medicines Agency, according to a Dompé press release.

The acceptance allows Oxervate, which was designated as an orphan drug by the EMA’s committee for Orphan Medicinal Products in 2015, to begin a scientific review procedure for marketing authorization, the release said.

The drug will most likely be assessed at an accelerated rate designed for severe conditions that currently have no valid treatment options.